Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- 1st Patient Enrolled in Global COVID-19 Study for Eritoran, Apremilast
October 28, 2020
- Opdivo Plus Cabometyx Filed for RCC in Japan: Ono/Takeda
October 28, 2020
- Opdivo-Yervoy Pair Filed for Malignant Pleural Mesothelioma in Japan
October 28, 2020
- Eisai Snaps Up Worldwide Rights for All of Cogstatethe’s Cognitive Function Tests
October 28, 2020
- Takeda Files Japan NDA for Short Bowel Syndrome Drug
October 28, 2020
- Sumitomo Dainippon Links Up with US Health Tech for R&D on Blood Collection and Stabilization Device
October 28, 2020
- Pharma’s Half-Year Earnings Season in Full Swing from This Week
October 27, 2020
- Ono Says Honjo’s 22.6 billion Yen Claim Groundless, No Agreement Reached on 40% Opdivo Fee Proposal
October 27, 2020
- Medicago Inks COVID-19 Vaccine Deal with Canadian Govt
October 27, 2020
- NC-6004-Keytruda Combo Racks Up Positive US PIIa Results for Head and Neck Cancer: NanoCarrier
October 27, 2020
- CureApp Launches Prescription Platform for Therapeutic Apps
October 26, 2020
- Mitsubishi Chemical Taps Belgium-Born Gilson as Its First Foreign CEO
October 26, 2020
- Exploratory Trial of Neuro-Protective/Regenerative Sheets to Be Launched for CTS: Osaka Univ., NIMS, Nippon Zoki
October 26, 2020
- Nichi-Iko’s Remicade Biosimilar Adds Ankylosing Spondylitis Use
October 26, 2020
- Sanwa Kagaku’s SHPT Drug Meets Primary Goal in Japan PIII
October 26, 2020
- Cyberattacks Leak Data from Shionogi’s Taiwan Subsidiary
October 26, 2020
- Novartis Looks to Solidify Presence in Multiple Sclerosis Arena with Mayzent, then Ofatumumab
October 23, 2020
- Chugai Enjoys Higher Earnings in January-September on Hemlibra
October 23, 2020
- Fujifilm Taps Carelink as Chinese Partner for Avigan
October 23, 2020
- Daiichi Sankyo Kicks Off PI Study for I/O Therapy DS-1055
October 23, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…